{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:43:51Z","timestamp":1777866231227,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["IDSEP130018"],"award-info":[{"award-number":["IDSEP130018"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["IDSEP130015"],"award-info":[{"award-number":["IDSEP130015"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["FHI360"],"award-info":[{"award-number":["FHI360"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2019.11.059","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T08:57:45Z","timestamp":1575449865000},"page":"1541-1550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Phase 2\/3 double blinded, randomized, placebo-controlled study in healthy adult participants in Vietnam to examine the safety and immunogenicity of an inactivated whole virion, alum adjuvanted, A(H5N1) influenza vaccine (IVACFLU-A\/H5N1)"],"prefix":"10.1016","volume":"38","author":[{"given":"Tran Nhu","family":"Duong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vu Dinh","family":"Thiem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dang Duc","family":"Anh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen Phu","family":"Cuong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tran Cong","family":"Thang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vu Minh","family":"Huong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vien Chinh","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen Thi Lan","family":"Phuong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7595-4974","authenticated-orcid":false,"given":"Emanuele","family":"Montomoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee","family":"Holt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco Berlanda","family":"Scorza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5069-1186","authenticated-orcid":false,"given":"Jorge","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5842-8622","authenticated-orcid":false,"given":"Tushar","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.11.059_b0005","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0140-6736(97)11212-0","article-title":"Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus","volume":"351","author":"Claas","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.11.059_b0010","unstructured":"World Health Organization. Influenza. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. 2 March 2018. http:\/\/www.who.int\/influenza\/human_animal_interface\/2018_03_02_tableH5N1.pdf?ua=1 (Accessed on 20 Mar 2018)."},{"key":"10.1016\/j.vaccine.2019.11.059_b0015","unstructured":"World Health Organization. Global pandemic influenza action plan to increase vaccine supply Available on: http:\/\/apps.who.int\/iris\/bitstream\/10665\/69388\/1\/WHO_IVB_06.13_eng.pdf (Accessed on 20 Mar 2018)."},{"issue":"45","key":"10.1016\/j.vaccine.2019.11.059_b0020","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1016\/j.vaccine.2016.08.055","article-title":"Clinical testing of an inactivated influenza A(H5N1) vaccine candidate in a double-blinded, placebo-controlled, randomized trial in healthy adults in Vietnam","volume":"34","author":"Phan","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.059_b0025","unstructured":"Guidance on clinical trial of influenza vaccine. Ministry of Health, Vietnam, 2013."},{"key":"10.1016\/j.vaccine.2019.11.059_b0030","unstructured":"European Agency for the Evaluation of Medical Products - Human Medicines Evaluation Unite. Note for guidance on clinical evaluation of new vaccines. London, May 1999; CPMP\/EWP\/463\/97. Available from http:\/\/www.eudra.org\/emea.html."},{"key":"10.1016\/j.vaccine.2019.11.059_b0035","unstructured":"Food and Drug Administration. Licensure of pandemic influenza vaccines: Demonstration of effectiveness. FDA Briefing document on vaccine and related Biological Products Advisory Committee meeting. February 29, 2012."},{"key":"10.1016\/j.vaccine.2019.11.059_b0040","unstructured":"Manual for the laboratory diagnosis and virological surveillance of influenza. WHO Global Influenza Surveillance Network, 2011; Available on http:\/\/apps.who.int\/iris\/bitstream\/10665\/44518\/1\/9789241548090_eng.pdf (accessed on 22\/Mar\/2018)."},{"key":"10.1016\/j.vaccine.2019.11.059_b0045","doi-asserted-by":"crossref","unstructured":"Ehrlich HJ, M\u00fcller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, L\u00f6w-Baselli A, Vartian N, Bobrovsky R, Pavlova BG, P\u00f6llabauer EM, Kistner O, Barrett PN; Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med. 2008; 358(24): 2573-84. http:\/\/doi.org\/10.1056\/NEJMoa073121.","DOI":"10.1056\/NEJMoa073121"},{"key":"10.1016\/j.vaccine.2019.11.059_b0050","unstructured":"Finney DJ. Statistical Methods in Biological Assay, 2nd ed., Griffin, London, England, 196."},{"key":"10.1016\/j.vaccine.2019.11.059_b0055","first-page":"43","article-title":"Single-radial-haemolysis: a new method for the assay of antibody to influenza haemagglutinin","volume":"52","author":"Schild","year":"1975","journal-title":"Bull World Health Organization"},{"key":"10.1016\/j.vaccine.2019.11.059_b0060","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0092-1157(77)80008-5","article-title":"An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines","volume":"5","author":"Wood","year":"1977","journal-title":"J Biol Stand"},{"issue":"9523","key":"10.1016\/j.vaccine.2019.11.059_b0065","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(06)68656-X","article-title":"Safety and immunogenicity of an inactivated split-virion influenza A\/Vietnam\/1194\/2004 (H5N1) vaccine: phase I randomised trial","volume":"367","author":"Bresson","year":"2006","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2019.11.059_b0070","first-page":"707","article-title":"Overview of serological techniques for influenza vaccine evaluation: past","volume":"2","author":"Trombetta","year":"2014","journal-title":"Present Future Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2019.11.059_b0075","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jviromet.2008.06.016","article-title":"WC. Increased sensitivity for detecting avian influenza-specific antibodies by a modified hemagglutination inhibition assay using horse erythrocytes","volume":"153","author":"Jia","year":"2008","journal-title":"J Virol Methods."},{"issue":"5","key":"10.1016\/j.vaccine.2019.11.059_b0080","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2471\/BLT.13.124412","article-title":"Influenza seasonality and vaccination timing in tropical and subtropical areas of southern and south-eastern Asia","volume":"92","author":"Saha","year":"2014","journal-title":"Bull World Health Organ."},{"issue":"4","key":"10.1016\/j.vaccine.2019.11.059_b0085","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/14787210.2016.1155450","article-title":"Influenza infection in human host: challenges in making a better influenza vaccine","volume":"14","author":"Virk","year":"2016","journal-title":"Expert Rev Anti Infect Ther."},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2019.11.059_b0090","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2014.12.020","article-title":"Variation in the human immune system is largely driven by non-heritable influences","volume":"160","author":"Brodin","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2019.11.059_b0095","first-page":"63","article-title":"Haemagglutination-inhibiting antibody to influenza virus","volume":"115","author":"de Jong","year":"2003","journal-title":"Dev Biol (Basel)."},{"issue":"1","key":"10.1016\/j.vaccine.2019.11.059_b0100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/oxfordjournals.bmb.a071545","article-title":"Determinants of immunity to influenza infection in man","volume":"35","author":"Potter","year":"1979","journal-title":"Br Med Bull."},{"issue":"6","key":"10.1016\/j.vaccine.2019.11.059_b0105","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1128\/CVI.00065-14","article-title":"Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients","volume":"21","author":"van der Velden","year":"2014","journal-title":"Clin Vaccine Immunol."},{"issue":"50","key":"10.1016\/j.vaccine.2019.11.059_b0110","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1016\/j.vaccine.2008.08.046","article-title":"Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children","volume":"26","author":"Nolan","year":"2008","journal-title":"Vaccine."},{"issue":"13","key":"10.1016\/j.vaccine.2019.11.059_b0115","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1016\/j.vaccine.2019.11.059_b0120","unstructured":"Prescribing information, Influenza Virus Vaccine, H5N1, Sanofi Pasteur, Available on https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM112836.pdf (site accessed on 29 Mar 2018)."},{"key":"10.1016\/j.vaccine.2019.11.059_b0125","doi-asserted-by":"crossref","first-page":"e49704","DOI":"10.1371\/journal.pone.0049704","article-title":"A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine","volume":"7","author":"Couch","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.11.059_b0130","first-page":"431","article-title":"Vaccines for pandemic influenza: summary of recent clinical trials","volume":"333","author":"Keitel","year":"2009","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"2","key":"10.1016\/j.vaccine.2019.11.059_b0135","doi-asserted-by":"crossref","first-page":"e4384","DOI":"10.1371\/journal.pone.0004384","article-title":"MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults","volume":"4","author":"Banzhoff","year":"2009","journal-title":"PLoS ONE"},{"issue":"14","key":"10.1016\/j.vaccine.2019.11.059_b0140","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1471-2334-14-142","article-title":"Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults","volume":"15","author":"Gillard","year":"2014","journal-title":"BMC Infect Dis."},{"issue":"4","key":"10.1016\/j.vaccine.2019.11.059_b0145","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/infdis\/jiv087","article-title":"Safety and immunogenicity of a single low dose or high dose of clade 2 influenza A(H5N1) inactivated vaccine in adults previously primed with clade 1 influenza A(H5N1) vaccine","volume":"212","author":"Winokur","year":"2015","journal-title":"J Infect Dis."},{"issue":"45","key":"10.1016\/j.vaccine.2019.11.059_b0150","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1016\/j.vaccine.2016.08.019","article-title":"The 2015 global production capacity of seasonal and pandemic influenza vaccine","volume":"34","author":"McLean","year":"2016","journal-title":"Vaccine."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:15:44Z","timestamp":1777536944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19316019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X19316019"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.11.059","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 2\/3 double blinded, randomized, placebo-controlled study in healthy adult participants in Vietnam to examine the safety and immunogenicity of an inactivated whole virion, alum adjuvanted, A(H5N1) influenza vaccine (IVACFLU-A\/H5N1)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.11.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}